The US Food and Drug Administration (FDA) has approved Janssen Pharmaceuticals’ Invokamet, a fixed-dose combination therapy of the company’s Invokana (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with Type 2 diabetes.

Invokament is a combination of a sodium glucose co–transporter 2 (SGLT2) inhibitor, canagliflozin and metformin. It was previously approved by the FDA in August 2014 as an adjunct to diet and exercise to improve blood glucose control in adults with Type 2 diabetes not adequately controlled by either canagliflozin or metformin, or who are already being treated with both medications separately. This new approval allows Invokament to be prescribed in adults with Type 2 diabetes who are not already being treated with canagliflozin or metformin and may benefit from dual therapy.

Source: Johnson & Johnson